Blue Jet Health

Blue Jet Healthcare announced that the groundbreaking ceremony for its Vizag project is scheduled for this month. This Greenfield site is envisioned as a pivotal growth platform, with Phase-1 dedicated to API and intermediates for new products aligned with customer requirements. The board has approved a total investment plan of Rs.1,000 crores over the next three to four years, with initial capacities aligned to customer demand. Management believes the scale, infrastructure, and geographic advantage of Vizag will strengthen its positioning as a reliable global partner in complex chemistries.

The company has secured lease space for R&D activities in Hyderabad, with development work expected to commence from Q3 FY27. This expansion involves an investment of approximately Rs.40 crores and aims to strengthen the innovation pipeline and technical capabilities. The focus areas include emerging technologies, intermediates for GLP-1s, peptide chemistry, and bio-catalysis. Blue Jet is currently tracking around 20 active RFPs, including six high-conviction phase-3 programs and two commercial products.

As part of its focus on specialty ingredients, Blue Jet Healthcare is initiating a few exhibit batches of a new artificial sweetener in FY27. This new product is expected to complement the existing high-intensity sweetener portfolio and address a growing segment of global demand. Management indicated that the target capacity or market potential for this new sweetener is about 10% or $1 billion, with key milestones expected between FY27 and FY28.

The expansion project at Mahad Unit-3, which focuses on backward integration into contrast media intermediates, is nearing completion. This facility, designed for a key side chain in the contrast media portfolio, incorporates robust safety, environmental, and automation systems. It has incurred a cumulative CAPEX of approximately Rs.146 crores to-date and is expected to be ready for qualification in Q1 FY27. This unit is anticipated to play a crucial role in de-bottlenecking the supply chain and supporting future growth.

For Q3 FY26, Blue Jet Healthcare reported a 40% YoY decrease in revenue from operations to Rs.192.4 crores, though it saw a 16% QoQ increase. EBITDA declined by 62% YoY and 15% QoQ, resulting in a 24% EBITDA margin. PAT also decreased by 39% YoY and 23% QoQ. The gross margin for Q3 was 52%, attributed to a change in product mix and a one-time^📎 inventory write-off. For the nine months ended December 31, 2025, revenue from operations increased by 3% YoY, while EBITDA and PAT both decreased by 6% YoY, with a gross margin of 53% compared to 50% last year.

Management acknowledged that the subdued orders for its flagship PI/API product are due to channel inventory de-stocking and supply chain realignment. They estimate that it might take a couple of quarters for the situation to get completely realigned. Despite this, they remain 'very bullish' on the product, noting its end molecule is showing good mid-level two-digit growth and opening up in new markets like Japan. The company expects volumes to revive soon, supported by binding forecasts and confirmed purchase orders.

Blue Jet Healthcare continues to integrate sustainability into its operations, with 70% of its power consumption now met through wind and solar sources. The company emphasizes atom efficiency in synthetic chemistry and sustainable process design, having recently been recognized with the National Award for Excellence in Energy Management by CII. Furthermore, a dedicated process excellence department has been established, supported by strong additions in engineering, quality, and supply chain to enhance reliability and responsiveness.